Positioning of proteasome inhibitors in therapy of solid malignancies

机译：蛋白酶体抑制剂在实体恶性肿瘤治疗中的位置

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

Targeting of the protein degradation pathway, in particular, the ubiquitin-proteasome system, has emerged as an attractive novel cancer chemotherapeutic modality. Although proteasome inhibitors have been most successfully applied in the treatment of hematological malignancies, they also received continuing interest for the treatment of solid tumors. In this review, we summarize the current positioning of proteasome inhibitors in the treatment of common solid malignancies (e.g., lung, colon, pancreas, breast, and head and neck cancer), addressing topics of their mechanism(s) of action, predictive factors and molecular mechanisms of resistance.

机译：靶向蛋白质降解途径，特别是泛素-蛋白酶体系统，已经成为一种有吸引力的新型癌症化学治疗方法。尽管蛋白酶体抑制剂已最成功地用于治疗血液系统恶性肿瘤，但它们也一直受到对实体瘤治疗的持续关注。在这篇综述中，我们总结了蛋白酶体抑制剂在治疗常见的实体恶性肿瘤（例如，肺癌，结肠癌，胰腺癌，乳腺癌以及头颈癌）中的定位，探讨了其作用机理，预测因素和抗性的分子机制。

著录项

期刊名称 Springer Open Choice
作者
Margot S. F. Roeten; Jacqueline Cloos; Gerrit Jansen;
展开▼
作者单位

展开▼
年(卷),期 -1(81),2
年度 -1
页码 227–243
总页数 17
原文格式 PDF
正文语种
中图分类外科学;
关键词
Proteasome inhibitors Bortezomib Carfilzomib Solid tumors Drug resistance;

机译：蛋白酶体抑制剂;硼替佐米;卡非佐米;实体瘤;耐药性;

相似文献

外文文献
中文文献
专利

1. Positioning of proteasome inhibitors in therapy of solid malignancies [J] . Margot S. F. Roeten, Jacqueline Cloos, Gerrit Jansen Cancer chemotherapy and pharmacology. . 2018,第2期

机译：蛋白酶体抑制剂在固体恶性肿瘤治疗中的定位
2. Phase 1b trial of proteasome inhibitor carfilzomib with irinotecan in lung cancer and other irinotecan-sensitive malignancies that have progressed on prior therapy (Onyx IST reference number: CAR-IST-553) [J] . Arnold Susanne M., Chansky Kari, Leggas Markos, Investigational new drugs. . 2017,第5期

机译：蛋白酶体抑制剂Carfilzomib的第1B期与肺癌和其他在此先前治疗的伊喹丹敏感恶性肿瘤（Onyx IST参考编号：Car-IST-553）的蛋白酶体抑制剂和其他恶性肿瘤的试验
3. Combination of a selective activator of the glucocorticoid receptor Compound A with a proteasome inhibitor as a novel strategy for chemotherapy of hematologic malignancies [J] . LesovayaE., YemelyanovA., KirsanovK., Cell cycle . 2013,第1期

机译：糖皮质激素受体化合物A的选择性激活剂与蛋白酶体抑制剂的组合作为血液系统恶性肿瘤化疗的新策略
4. Controlled Release of Proteasome Inhibitor from Biodegradable Nanoparticles for Myeloma Therapies [C] . Gianni Rossini, Jack Trevino, Neal Vail Controlled Release Society Annual Meeting and Exposition . 2007

机译：蛋白酶体抑制剂从可降解纳米粒用于骨髓瘤治疗的控制释放。
5. The Design and Synthesis of Novel Proteasome Inhibitors: Studies on the Synthesis of Nagelamide M and Analogs, the Synthesis of Rapamycin Based Proteasome Inhibitors, and the Synthesis of TCH Based Molecular Probes for Binding Site Determination. [D] . Giletto, Matthew Basil. 2017

机译：新型蛋白酶体抑制剂的设计与合成：Nagelamide M和类似物的合成，雷帕霉素基蛋白酶体抑制剂的合成以及TCH基分子探针的结合位点测定的研究。
6. Combination of a selective activator of the glucocorticoid receptor Compound A with a proteasome inhibitor as a novel strategy for chemotherapy of hematologic malignancies [O] . Ekaterina Lesovaya, Alexander Yemelyanov, Kirill Kirsanov, 2013

机译：糖皮质激素受体化合物A的选择性激活剂与蛋白酶体抑制剂的组合作为血液系统恶性肿瘤化疗的新策略
7. Phase 1b trial of proteasome inhibitor carfilzomib with irinotecan in lung cancer and other irinotecan-sensitive malignancies that have progressed on prior therapy (Onyx IST reference number: CAR-IST-553) [O] . 2017

机译：蛋白酶体抑制剂卡非佐米与伊立替康治疗肺癌和其他对伊立替康敏感的恶性肿瘤的1b期临床试验已在先前治疗中取得进展（Onyx IST参考编号：CAR-IST-553）
8. Enzymatic Activation of Proteasome Inhibitor Prodrugs by Prostate- Specific Antigen as Targeted Therapy for Prostate Cancer. [R] . Denmeade, S. R. 2002

机译：前列腺特异性抗原对蛋白酶体抑制剂前药的酶促活化作为前列腺癌的靶向治疗。

Positioning of proteasome inhibitors in therapy of solid malignancies

摘要

著录项

相似文献

相关主题

期刊订阅